The cystic fibrosis transmembrane conductance regulator (CFTR) functions to regulate both Cl-and Na ÷ conductive pathways; however, the cellular mechanisms whereby CFTR acts as a conductance regulator are unknown. CFTR and outwardly rectifying Cl-channels (ORCCs) are distinct channels but are linked functionally via an unknown regulatory mechanism. We present results from whole-cell and single-channel patch-clamp recordings, short-circuit current recordings, and [7-3=P]ATP release assays of normal, CF, and wild-type or mutant CFTR-transfected CF airway cultured epithelial cells wherein CFTR regulates ORCCs by triggering the transport of the potent agonist, ATP, out of the cell. Once released, ATP stimulates ORCCs through a P=u purinergic receptor-dependent signaling mechanism. Our results suggest that CFTR functions to regulate other Cl-secretory pathways in addition to itself conducting CI-.
Introduction
P. M. Quinton discovered that secretory epithelia derived from cystic fibrosis (CF) patients have low CI-conductance (Quinton, 1983) . Subsequent identification and cloning of the CF gene Riordan et al., 1989) led to many studies that demonstrated convincingly that the cystic fibrosis transmembrane conductance regulator (CFTR) is a linear, cAMP-activated 8-10 pS chloride channel (Cliff et al., 1992) .
It is also known that, in addition to functioning as a CIchannel, CFTR controls the regulation of other transport pathways (Egan et al., 1992; Gabriel et al., 1993; Schwiebert et al., 1994a) . For example, patients with CF, and the CF (-/-) mouse, have enhanced Na ÷ absorption (Grubb et al., 1994; Chinet et al., 1994; Hyde et al., 1993; Alton et al., 1993) ; this enhanced Na ÷ absorption is corrected by addition of a wild-type copy of CFTR (Johnson et al., 1995; Hyde et al., 1993; Alton et al., 1993) . These data suggest that CFTR can interact with Na+-reabsorptive pathways. Likewise, in cells from CF patients, several laboratories showed that protein kinase A (PKA) regulation of outwardly rectifying CI-channels (ORCCs) is defective compared with that of normal epithelia. Complementation of CF airway epithelial cells with the wild-type CF gene corrects PKA regulation of ORCCs (Egan et al., 1992; Gabriel et al., 1993; Schwiebert et al., 1994a) . The biophysical properties of ORCCs, which include a large conductance (30-70 pS), a rectifying current-voltage (I-V) relationship, sensitivity to 4,4'-diisothiocyanotostilbene-2,2'-disulfonic acid (DIDS), activation with depolariz!ng voltages, and a halide permselectivity of I-> CI-differ completely from CFTR channel properties (Hwang et al., 1989; Egan et al., 1992; Gabriel et al., 1993; Schwiebert et al., 1994a) . Evidence suggests that CFTR and ORCCs are encoded by separate genes (Gabriel et al., 1993) . Finally, it has been demonstrated that Ca2+-dependent CI-secretion is also up-regulated in CF patients and in the CF (-/-) mouse (Grubbet al., 1994) . This up-regulation of the Ca 2÷-dependent pathway is also corrected by wild-type CFTR transduction (Johnson et al., 1995) . Clearly, CFTR can control the function of both Na ÷ and CI-transport pathways.
Although it is known that CFTR can influence the regulation of distinct channel .types, their activity, or both, the question regarding the cellular mechanisms involved is unanswered. Several hypotheses that explain how CFTR might control ORCCs include direct protein-protein interaction, activation of a shared second messenger pathway, or the transport of a substance that could activate ORCCs. The purpose of this study was to define the cellular mechanisms whereby CFTR regulates ORCCs. Our results suggest that CFTR regulates ORCCs by triggering the transport and release of the potent autacoid agonist and ORCC regulator ATP.
Results

.j
Dependence of cAMP Activation of ORCCs on Intracellular ATP Previously, we showed that 5 mM intracellular Mg2+-ATP was required to maintain cAMP stimulation of ORCCs during whole-cell current recording and to prevent rundown or inactivation of ORCCs (Schwiebert et al., 1994a; Quinton and Reddy, 1992) . As illustrated in Figure 1A , the degree of outward rectification and the magnitude of the cAMP-activated CI-currents (Ic~(cAMp)) become larger with increasing concentrations of intracellular (pipette) ATP in whole-cell patch-clamp recordings of normal airway epithelial (9HTEo-) cells prestimulated in all cases with 8-(4-chlorophenylthio)-adenosine-3',5'.cyclic monophosphate (CPT-cAMP) (200 I~M) . This airway epithelial cell line has been used previously to study the wild-type properties of CFTR (Schwiebert et al., 1994a) . At 1 mM intracellular Mg2÷-ATP, I C~<cAMPI currents are linear ( Figure 1A) . A concentration of at least 2.5 mM intracellular Mg2+-ATP is necessary to begin to observe rectifying currents. At 5 mM or 10 mM intracellular Mg2+-ATP, cAMP-stimulated currents are clearly rectifying (Figure° 1A) . Outward rectifi- cation of ICKcAMP)is inhibited markedly by 5,11,17,23-tetrasulfonato-25,26,27,28-tetramet hoxy-calix[4] arene (TS-TMcalix[4]arene or TS-TM-Calix4) ( Figure 1B) ; ORCCs but not CFTR are inhibited by this CI-channel-blocking drug (Singh et al., 1993; Schwiebert et al., 1994a) . Interestingly, pretreatment of normal cells with glybenclamide, a CIchannel inhibitor specific for CFTR (Sheppard and Welsh, 1993) , blocked cAMP stimulation of both CFTR and ORCCs ( Figure 1B ). CPT-cAMP stimulation of rectifying currents does not occur either in IB3-1 CF bronchial epithelial cells or in ECFTE-29o-CF tracheal epithelial cells (n = 5-10 each; data not shown). Therefore, these data show that cAMP stimulation of ORCCs is dependent upon intracellular ATP and upon the expression of wild-type CFTR.
Effects of Extracellular ATP Trapping on cAMP Activation of ORCCs
To test the hypothesis that ATP acts extracellularly in cAMP stimulation of ORCCs, whole-cell recordings were performed in the absence and presence of the ATP scavenger hexokinase in cells containing wild-type CFTR. Hexokinase traps ATP in solution by cleaving the y-phosphate of ATP and donating it to glucose, creating the end product glucose-6-phosphate. Glucose was present in all bath solutions. In the absence of hexokinase but with 5 mM Mg-ATP in the pipette and CPT-cAMP in the bath, IC,(cAMP (B) Left bar graph illustrating cAMP-activated whole-cell CI conductance (Gc,~cAMP)) at -100 mV and +100 mV command voltages in normal cells. Basal currents were minimal and were subtracted from cAMPstimulated currents to graph GC,i cAMP). The bar graph on the right summarizes results from IB3-1 cells transiently transfected with wild-type CFTR; results from nonresponding cells and responding cells with and without hexokinase are shown. Greater GC~(oAMP) at +100 mV when compared with GC,(cAMP) at -100 mV reflects outward rectification of GC,IcAMP). AS expected, 5 mM ATPyS with CPT-cAMP and 5 mM pipette Mg-ATP also failed to stimulate GCI in CF airway epithelial cells (data not shown). Data are expressed as mean _+ SEM. Asterisk, P < 0.05 when compared with response from CF cells; two asterisks, P < 0.05 refers to significant outward rectification of GCJCoAMP). Millimolar concentration of ATP or ATP'yS in the pipette is shown as 5 ATP or 5 ATPTS; Glu, HK/Glu, and apyrase refer to glucose, hexokinase (HK), both glucose and hexokinase, or apyrase in the bath for a given set of data. The number in parentheses is the number of experiments performed.
outwardly rectifying (Figures 2A and 2B ). However, in the presence of bath hexokinase, IC,(cAMP) is linear and timeand voltage-independent, consistent with stimulation of only CFTR CI-channels and not ORCCs (Figures 2A and 2B) . A different ATP scavenger, apyrase, an ATPase/ADPase isolated from potato, also prevented cAMP stimulation of ORCCs without affecting activation of CFTR currents ( Figure 2B ), suggesting that the effects of hexokinase and apyrase were due to ATP catalysis. When 5 mM ATPyS, a poorly hydrolyzable and hexokinase-resistant analog of ATP, was included in the pipette solution along with 5 mM Mg-ATP, IC,(cAMP)in the presence of hexokinase became Refers to significant difference between incidence of ORCC channels in the absence versus the presence of hexokinase in the pipette (extracellular) solution (P ~< 0.05; unpaired Student's t test analysis; Neuman-Keul's test). Moreover, in 4 out of the 8 patches that contained activated CFTR channels in the presence of hexokinase, ORCCs were also present as determined by stimulation elicited by depolarization. These ORCCs were, however, insensitive to PKA and ATP stimulation.
outwardly rectifying again ( Figure 2B ). Hexokinase was ineffective when glucose was omitted from the bath solution (data not shown). As expected, the presence of hexokinase had no effect on the inability of cAMP to stimulate CI-currents in CF cells (n = 5; data not shown). These data show that lack of activation of ORCCs in the presence of hexokinase or apyrase was indeed caused by ATP trapping and suggest that release of ATP into the extracellular solution from the epithelial cells themselves is important for activating ORCCs during cAMP stimulation. Whole-cell current experiments performed in the presence and absence of hexokinase in the bath on IB3-1 CF cells transiently transfected with wild-type CFTR gave similar resuits ( Figure 2B ), eliminating the possibility that the hexokinase inhibition of cAMP-stimulated outwardly rectifying currents is cell type-specific.
To study the effects of hexokinase on single ORCCs, excised, inside-out patch clamping was performed on IB3-1 CF cells complemented with wild-type CFTR (clone $9). As shown previously by utilizing this wild-type CFTRcomplemented IB3-1 cell line (Egan et al., 1992) , catalytic subunit of PKA (50 nM) and Mg-ATP (1 mM) added to the bath solution (cytoplasmic face of excised patches) activated both CFTR CI-channels and ORCCs (Table 1) . With hexokinase (0.2 U/ml) in the extracellular (pipette) solution, PKA and ATP activated only CFTR channels (Table 1); ORCCs were not activated in *any of the patches by PKA and ATP, although they were present in 4 out of 10 patches as determined by activation with depolarization ( in more detail the role of extracellular ATP in the activation of ORCCs by utilizing both cell-attached and whole-cell patch-clamp experiments. In cell-attached patches of CF cells complemented with wild-type CFTR ($9 cells), addition of 500 nM ATP as an agonist into the pipette and bath (extracellular) solutions stimulated ORCC single channels in 4 out of 4 patches upon formation of the cell-attached patch ( Figure 3A ). The open probability (Po) of the ORCC channels 1 min after patch formation in the presence of 500 nM ATPwas0.49 _.+ 0.11 (n = 4). In fiveother patches, no channel activity was observed; ORCCs were not contained in these patches, as determined by excision and depolarization. After 3 min, the Po decreased to 0.04 _+ 0.03 (n = 4). ATP (500 nM) stimulates ORCCs specifically; no other channels where observed in these experiments. The reversal potential (Erev) of corresponding I-V plots constructed from pipette voltages of ATP-stimulated ORCCs was +19.2 mV (the Nernst equations predict an E,ev of +32 mV if the channel is completely selective for CI-and if intracellular CI-concentration is assumed to be 39 mM) (Welsh, 1986) . Also assuming a resting membrane potential of -46 mV (Welsh, 1986) , the estimated and corrected Erev for ATP-stimulated ORCCs in cell-attached patches would be approximately -30 mV, consistent with stimulation of an ORCC CI-channel by 500 nM ATP.
Extracellular ATP at nanomolar doses in the absence of cAMP also stimulated outwardly rectifying whole-cell CI-currents in both normal and CF cells ( Figure 3B ). Stimulation of outwardly rectifying whole-cell CI-currents by na~omolar doses of extracellu liar ATP was in hibited markedly by TS-TM-calix[4]arene, demonstrating that the currents are generated specifically by ORCCs ( Figure 3C ). Stimulation of ORCCs with external ATP at 100 nM doses was biphasic, consisting of both transient and sustained components of stimulated current. At higher concentrations of extracellular ATP added to the bath solution, multiple types of whole-cell CI-currents were activated. Figure  3D shows an example of at least three types of whole-cell CI-currents activated in a time-dependent manner by 10 I~M ATP. Outwardly rectifying currents were activated initially and were later masked by activation of linear and inwardly rectifying currents. Stimulation with micromolar doses of ATP also induced transient and sustained current responses. Because of the multiplicity of ATP-activated currents observed at the higher doses, we focused specifically on the effects of lower dose (nanomolar) stimulation by ATP.
ORCC currents in both normal and CF cells are activated equivalently by nanomolar doses of extracellular ATP (Figure 3E) . Therefore, unlike cAMP-dependent activation, which only occurs in the presence of wild-type CFTR, external ATP stimulates ORCCs independently of CFTR. The stimulation of ORCCs by external ATP is most likely via a purinergic receptor expressed in the plasma membrane. To gain more information on which subtype of purinergic receptor is involved in the stimulation of ORCCs, 500 nM external ATP was compared with other nucleotides, such as GTP, AMP, ADP, ATPTS, and UTP, in whole-cell recordings of normal airway epithelial (9HTEo-) cells. Antagonists and agonists selective or specific for the five or more different subtypes of P2 purinergic receptors are not available (Barnard et al., 1994) . A dose of 500 nM was used, because this dose produced a potent yet specific stimulation of ORCC currents. Figure 3F shows that UTP, ATP, and ATPTS were equipotent, whereas other nucleotides were less effective. The rank order potency for stimulation of ORCC currents was UTP/> ATP 1> ATPyS >> ADP > AMP = GTP ( Figure 3F ). Addition of AMP and GTP produced no significant increase in wholecell conductance ( Figure 3F ). This rank order of potency is most consistent with the affinity profile of a P2u purinergic receptor and suggests that ATP stimulates ORCCs via this purinergic receptor subtype (Lustig et a1.,o1993; Parr et al., 1994; Barnard et al., 1994) .
CFTR-Mediated ATP Transport
To demonstrate directly that CFTR triggers the transport of ATP out of cells, two independent experimental approaches were undertaken. First, excised, inside-out patch-clamp recordings of wild-type CFTR-complemented CF cells were studied to compare conduction of CI-anions with conduction of ATP-anions. PKA. and ATP-activated CFTR CI-channels had a conductance of 10 pS in symmetrical NaCI-containing solutions at both -50 mV and +50 mV. When the bath solution was switched to a Na2-ATPcontaining solution ([ATP], 50 mM), the conductance of this CFTR channel decreased from 10 pS to 5 pS at -50 mV (cytoplasmic side of the patch negative relative to the extracellular side of the patch), injected to drive anionic ATP from the cytoplasmic (bath) side of the membrane patch to the extracellular (pipette) side of the patch ( Table   2) . At +50 mV, a 10 pS CI-conductance was still measured (Table 2) . Moreover, when the bath solution was switched Table 2 . Chloride and ATP Single-Channel Conductances through CFTR Pipette Bath y (-50 m~ y (+50 mV) NaCI NaCI 9.7 ± 0.4 9.7 ± 0.4 NaCI Na2-ATP 5.1 ± 0.5 • 9.7 ± 0.4 NaCI NaCI 9.7 ± 0. drives anions from the cytoplasmic (bath) side of the membrane patch to the extracellular (pipette) side of the patch. In each experiment, no channel activity was measured for at least 5 min following excision, whereas subsequent addition of PKA and ATP opened these channels. CI-conductance is symmetrical Tris-CI solutions was 9.4 ± 0.26 pS, a value not different from NaCI-containing solutions. ATP conductance in symmetrical Tris-ATP solutions was 5.7 ± 0.3 pS, a value significantly different from the 9.4 ± 0.26 p~ CI-conductance. 7, single-channel conductance (in picosiemens). a Significant difference between ATP-conductance and CI-conductance. (B) Corresponding I-V plot for the same channel, where ATP-currents were observed at negative voltages and CI-currents at positive voltages (n = 9). The reversal potential of the measured current amplitudes was-22.0 _ 2.0 mV (n = 5). An accompanying I-V plot for ATPcurrents measured in symmetrical Tris-ATP is also shown. The I-V plot for CI-currents measured in symmetrical Tris-CI was linear with a slope conductance of 9.~ pS (see Table 2 for conductance data).
(<3) Bar graph illustrating percent cAMP-stimulated generation of glucose-6--32P in IB3-1 cells, IB3-1 cells stably transfected with an AAV inverted terminal repeat promotor-driven wildtype CFTR viral vector (Egan et al, 1992; Flotte et al., 1993; Schwiebert et al., 1994a) , or IB3-1 cells transiently transfected with wild-type or mutant CFTR (A455E-CFTR and G551D-CFTR). Data are expressed to percent change versus control. Data are expressed as mean _ SEM. Number in parentheses is number of experiments performed.
back to a CI--containing solution, the conductance returned from 5 pS to 10 pS at -50 mV. Both the 10 pS CIconductance and the 5 pS ATP 2-conductance were inhibited completely by glybenclamide (100 p.M, n = 3-5 each; Po decreased to 0.00). A 5 pS ATP conductance was also recorded with Naz-ATP ([ATP], 50 mM) in the bath and Na gluconate in the pipette solution (CI--free solutions in pipette and bath), but only at -50 mV, again designed to drive ATP anions from the cytoplasmic side of the patch to the extracellular side of the patch (Table 2) . Corresponding I-V plots of the ATP current amplitudes show that no currents were measured at positive voltages, since only gtuconate was present on that side of the patch (data not shown). These currents are not carried by Na + for the following reasons: first, Na ÷ concentrations are symmetrical in these CI--free conditions; second, such currents would be observed at both negative and positive voltages with similar amplitudes in these CI--free conditions; and third, the currents would be insensitive to glybenclamide. Also, similar differential conductances were observed in asymmetrical conditions with Tris-CI ([CI], 140 mM) in the pipette solution and Tris-ATP ([ATP], 140 mM) in the bath solution (Table 2 ). Figure 4A shows a single-channel current record that displays ATP-current amplitudes at -50 mV and CI-current amplitudes at +50 mV voltage in these asymmetrical conditions. The corresponding I-V plot illustrates the ATP-current amplitudes at negative voltages and the CI-current amplitudes at positive voltages ( Figure  4B ). The reversal potential (Erev) under these asymmetrical solutions was -22.0 _+ 2.0 mV, consistent with CI-being more permeable across the membrane patch. A linear I-V plot for ATP-currents was measured in symmetrical 140 mM Tris-ATP ( Figure 4B ). These results, in particular, also illustrate relative CI-versus ATP-conductances across the patch, which were 9 pS and 6 pS respectively (Table 2) . Finally, in symmetrical Tris-ATP solutions, the conductance was 6 pS at both -50 mV and +50 mY, consistent with the ATP-conductance measured in asymmetrical Tris-CI/Tris-ATP (Table 2) .
Second, to demonstrate that cAMP-dependent ATP release occurs from cells containing CFTR, IB3-1 CF cells or IB3-1 cells stably or transiently transfected with wildtype or mutant CFTR were loaded with high specific activity [.),-32P]ATP by use of a 15 min streptolysin O (1 U/ml) permeabilization procedure followed by vigorous washing and a 2 hr incubation with ['),-32P]ATP in a standard Ringer's solution (see Experimental Procedures). Release of [7-32P]ATP into the medium was measured over time with and without CPT-cAMP in Ringer's solution'that contained hexokinase (1 U/ml) to trap the [7-32P]ATP as glucose-6-32P. ATP release was stimulated by cAMP in cells either stably complemented (clones $9, 315A, and 6-wt-1) or transiently transfected with wild-type CFTR ( Figure 4C ). No cAMP-stimulated ATP release was observed in parental IB3-1 CF cells ( Figure 4C ). Glybenclamide (100 pM) inhibited completely cAMP-stimulated ATP release from stably complemented 315A cells ( Figure 4C ). Interestingly, two mutations located in the first nucleotide-binding domain of CFTR, A455E-CFTR, a mutation associated with mild CF pulmonary disease, and G551 D-CFTR, a mutation associated with severe CF lung disease, had different effects on the ability of CFTR to trigger ATP release. IB3-1 CF cells transiently transfected with A455E reestablished cAMP-stimulated ATP release, although the magnitude was not as large compared with wild-type CFTR ( Figure 4C ). In sharp contrast, G551D failed to complement cAMP-stimulated ATP release in IB3-1 CF cells (Figure 4C) .
Taken together, these data show that cells containing a wild-type copy of CFTR can release ATP in response to cAMP either through CFTR or via a closely associated ATP channel and that this release mechanism does not Figure 5 . ORCCs as Well as CFTR Contribute to cAMP-and ATPStimulated CI Secretion (A) Short-circuit current traces from a representative monolayer, showing the response to cAMP in the absence (upper left) and presence (lower left) of hexokinase (5 U/ml) pretreatment, cAMP stimulation in the presence and absence of hexokinase was performed on each monolayer; thus, the comparison of both conditions was paired. The response to cAMP was fully reversible. The effect of hexokinase when added at 2 rain (upper right) following cAMP stimulation is also shown. All experiments were performed in the presence of mucosal amiloride (10 IIM). The bar graph (lower right) illustrating percent inhibition of cAMP-stimulated I~ with hexokinase in the mucosal solution is also shown. Asterisk indicates significant inhibition (P < 0.05).
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occur in CF cells that contain CFTR bearing either AF508 (mutation in parental IB3-1 cells) or G551D mutations.
Role of ATP in a Polarized Epithelium
To determine whether ATP release can play a role in CIsecretion in a polarized epithelium and to evaluate the role for ORCCs in CI-secretion, short-circuit current (1~) recordings were performed on normal rat tracheal epithelial cells grown in primary culture on permeable supports. All experiments were performed in the presence of apical amiloride (10 p,M). Basolateral addition of 8-bromo-cAMP (200 I~M) increased I~ ( Figure 5A ) in a monophasic manner, as expected for these normal airway epithelial cells. Pretreatment with hexokinase (5 U/ml; 5 mM glucose is present in the bath solution, pre-cAMP in Figure 5A ) added to the apical solution, however, attenuated cAMP stimulation of I~ by 40.0% ± 7.7% (n = 9). Hexokinase added to the serosal solution had no effect on cAMP stimulation of Isc (data not shown). Addition of hexokinase following cAMP stimulation (post-cAMP, Figure 5A ) inhibited I~ by 31.0% ± 3.2o/0 (n = 8). The hexokinase-insensitive I~ was inhibited completely by glybenclamide (100 I~M; Figure 5A ).
Several CI-Pathways Contribute to cAMP-and ATP-Stimulated CI-Secretion
To evaluate the contribution of individual CI-secretory pathways in cAMP-stimulated and ATP-stimulated CI-secretion, the effect of CI-channel-blocking agents selective for CFTR (glybenclamide) (Sheppard and Welsh, 1993) , selective for ORCCs (TS-TM-calix[4]arene, DIDS) (Singh et al., 1993; Schwiebert et al., 1994a; Cliff et al., 1992) , or selective for both CFTR and ORCCs (diphenylamine carboxylic acid [DPC]) (Cliff et al., 1992; Schwiebert et al,, 1994a ) was examined. Pretreatment of rat tracheal epithelial monolayers with glybenclamide (100 I~M) or DPC (5 mM) completely blocked cAMP-stimulated I,c ( Figure 5B ). In contrast, components of the cAMP-stimulated Isc were inhibited either by TS-TM-calix[4]arene (21%, 1 ~M)~or DIDS (310/0, 1 mM) with subsequent addition of glybenclamide inhibiting the remaining portion (66%, Figure 5B ). Complete inhibition with glybenclamide pretreatment is consistent with wholecell patch-clamp experiments (see Figure 1B ) and sug-(B) Representative short-circuit current recordings illustrating sensitivity of cAMP-stimulated I~ to DIDS and to glybenclamide and bar graph summary of results with CI-channel inhibitors. In the upper right panel of (A), the differential effects of TS-TM-calix[4]arene and glybenclamide are shown as well. I~ with 8-Br-cAMP was 47.8 _+ 1 t .6 p.Ncm 2 (n = 12). The summary reflects results from maximal doses of DPC (5 raM), glybenclamide (100 p.M), TS-TM-Calix4 (1 p.M), and DIDS (1 raM). Asteris k indicates significant inhibition (P < 0.05). gests that this inhibitor disrupts both CFTR CI-channel function and cAMP-and CFTR-dependent ATP release. Indeed, glybenclamide also inhibited ATP conductance (see above) and ATP release (see Figure 4C ). As observed in whole-cell patch-clamp experiments, as little as 1-10 nM ATP added to the apical side of monolayers stimulated I~; ATP increased I.c in these monolayers in a dose-dependent manner between 100 nM and 5 ~M ( Figure 5C ). This activation was biphasic, consisting of transient and sustained components ( Figure 5C ). Of interest, the response was less robust at 50 I~M ( Figure 5C ). Addition of DIDS (1 mM) or TS-TM-calix[4]arene (1 pM) blocked almost completely the sustained current after ATP stimulation ( Figure 5C ). Pretreatment with DIDS, however, completely blocked responses to nanomolar doses of ATP but only partially inhibited responses to micromolar doses of ATP. The DIDS-insensitive component of Isc was inhibited completely by glybenclamide (100 I~M).
These results show that a portion of cAMP-dependent CI-secretion is inhibited by hexokinase and depends upon the release of ATP as an autocrine or paracrine agonist. The results also show that several apical CI-secretory pathways contribute to cAMP-and to ATP-stimulated CIsecretion in rat tracheal epithelium; these include glybenclamide, TS-TM-calix[4]arene, and DIDS-sensitive components. Importantly, when stimulated by nanomolar doses of ATP, the TS-TM-calix[4]arene-and DIDS-sensitive components predominate. Taken together with the data from single-channel and whole-cell patch-clamp experiments, these data are consistent with involvement of multiple channel types, including ORCCs, in CI-secretion in the airway and demonstrate that ORCCs are physiologically relevant to airway surface epithelial CI-secretion.
Discussion
Initial hypotheses on the function of CFTR, the cystic fibrosis transmembrane conductance regulator, shortly after the CF gene was cloned and sequenced suggested that the CF gene product may function as a conductance regulator. Our data are consistent with the cellular model, shown in Figure 6 , of how CFTR is a regulator of multiple CI--secretory pathways. Cyclic AMP-and PKA-stimulated CFTR, in addition to conducting CI-ions, either conducts ATP out of the cell, down a favorable concentration gradient, or regulates a closely associated ATP release channel. Once released from the cell, ATP as an agonist stimulates ORCCs through activation of P2u purinergic receptors. Activated P2u purinergic receptors, either through direct coupling to the ORCC or through a G protein-coupled signaling pathway, stimulate ORCCs and, most likely, other CI-channels to conduct more Cl-oions out of the cell into the airway.
A key observation is that ATP scavengers such as hexokinase and apyrase inhibit very effectively cAMP and PKA activation of outwardly rectifying whole-cell CI-currents and single-channel events and a component of CI-secretion in a tracheal epithelium expressing wild-type CFTR. The inhibition of ORCC activation by these agents occurs without any effect on CFTR-driven currents. Thus, extracellular ATP scavengers dissociate cAMP activation of CFTR from ORCCs. A lack of activation of ORCCs by PKA had only been noted previously in the presence of AF508-CFTR in CF airway epithelia (Egan et al., 1992) or in CF (-/-) mouse airway epithelia (Gabriel et al., 1993) . The observation that extracellular hexokinase can convert ORCCs from a PKA-sensitive mode to one that is PKAinsensitive in the continued presence of wild-type CFTR, a result similar to that observed previously only in CF cells, points strongly to a role of extracellular ATP, released by the epithelium itself, in this process.
It is well known that ATP, presumably via a purinergic receptor in the apical cell membrane, can stimulate CIsecretion in both CF and normal epithelia when applied in micromolar concentrations (Knowles et al., 1991; Clarke and Boucher, 1992) . Experiments in this study have provided both additional and novel results to show that nanomolar concentrations of extr~cellular ATP and other nucleotides (UTP, ATP~,S) can stimulate ORCCs in normal and CF airway epithelial cells. In addition, larger doses of ATP (10 ~M) stimulated ORCCs as well as other CI-conductances in a time-dependent manner. These results agree with those of Stutts and coworkers, who have shown stimulation of multiple conductances by ATP at doses between 100 p.M and 1 mM . The profile of potency of individual nucleotides, especially the similar potency of UTP and ATP, suggests that a P2u or P2¥2 subtype of purinergic receptor plays a role (Lustig et al., 1993; Barnard et al., 1994) in the apical membrane of human airway epithelia. ATP activation of ORCCs was demonstrated in whole-cell and single-channel patch-clamp recordings with cytoplasmic Ca 2÷ buffered to 100 nM; it is unlikely that signal transduction pathways involving an increase in intracellular Ca 2÷ mediate the response in patchclamp experiments. It is possible, however, that Ca2+~, at least in part, is responsible for ATP stimulation of secretory CI-current in short-circuit current experiments.
Our results pointing to a regulatory role for external ATP raise the question of the source of external ATP. In all experimental assays, the only source of ATP is the epithelial cells themselves, unless ATP is added as an agonist artificially. As early as 1986, the biological activity of ATP as an agonist had already been studied extensively and reviewed (Gordon, 1986) . In this study, we have also demonstrated that airway epithelial cell lines containing a normal copy of CFTR can promote the release of ATP upon stimulation by cAMP. This cAMP-stimulated ATP release is inhibited completely by glybenclamide, a CFTR channel inhibitor, and does not occur in CF epithelial cells, suggesting an involvement of CFTR itself in the ATP release mechanism or CFTR regulation of a closely associated ATP release channel. Further support for this hypothesis is that CFTR bearing an A455E mutation, which is associated with mild CF lung disease, can induce ATP release, whereas CFTR bearing a more severe G551D mutation fails to trigger ATP release. In a separate study, it was shown that both of the mutant forms of CFTR, A455E and G551D, could function as cAMP-activated CI-channels, although the function of G551D was much reduced compared with that of wild-type or A455E CFTR (Fulmer et al., 1995) . Importantly, only A455E and not G551D could correct cAMP regulation of ORCCs in IB3-1 CF cells (Fulmer et al., 1995) . This result suggests that the ability of CFTR to form a CI-channel does not necessarily correlate with its ability to induce ATP release or perform its conductance regulator functions. The possibility that CFTR could be involved in ATP reI~ase from cells was proposed first by H. F. Cantiello and collaborators (Reisin et al., 1994) . In this study, we provided additional evidence that CFTR can either conduct ATP or affect the release of ATP from the cell by regulating an ATP release mechanism. For example, in excised patch-clamp recordings of single CFTR CI-channels, single-channel events can be observed with ATP-as the only permeant anion on the cytoplasmic side of a patch, which in CI--containing solutions was verified to possess only CFTR CI-channels. Both CFTR CI-and ATP-singlechannel conductances are blocked completely by glybenclamide. ATP single-channel conductance through CFTR channels was approximately 6 pS, in agreement with the value derived from previous experiments (Reisin et al., 1994) . Moreover, the design of the CI--free patch-clamp experiment and results from experiments in Tris solutions suggest that anionic conductances are being measured in these experiments. Clearly, the simplest interpretation is that CFTR itself can conduct ATP; however, it is also possible that, through its role as a conductance regulator, CFTR can affect the release of ATP through a closely related but separate channel.
By transporting CI-itself and by activating other CIchannels, CFTR could magnify its role in CI-secretion despite its low expression in airway surface epithelia (Chu et al., 1991) . Finally, the role of CFTR as a conductance regulator may also explain why only a relatively small amount of wild-type CFTR is necessary to achieve a clinically normal CI-secretory phenotype in the airway (Chu et al., 1991) . Since only low levels of CFTR need to be expressed to achieve normal function, this observation has important implications for the level of expression necessary for gene therapy approaches to be efficacious along the airway. Although it is clear that extracellular ATP can activate ORCCs and other channels, that CFTR plays a role either direct or regulatory in the release of ATP, and that the two functions and channels are linked, it is likely that additional mechanisms may also participate in the interaction of CFTR and other transport processes in secretory epithelia.
Experimental Procedures
Cell Culture All studies were performed on human airway epithelial cell lines characterized and utilized for physiology in previous studies (Gruenert et al., 1988; Schwiebert et al., 1992; Schwiebert et al., 1994a; Schwiebert et al., 1994b; Egan et al., 1992; Kunzelmann et al., 1993; Zeitlin et al., 1991) . 9HTEo-cells are a normal tracheal epithelial cell line that expresses wild-type CFTR (Gruenert et al., 1988; Schwiebert et al., 1992; Schwiebert et al., 1994b ; E. M. S., M. M. Morales, and W. B. G., unpublished data). ]~CFTE-29o-cells are a CF human tracheal epithelial cell line derived from a CF patient homozygous for the ~,F508 mutation (Kunzelmann et al., 1993) . Each cell line was cultured as described previously in detail (Gruenert et al., 1988; Kunzelmann et al., 1993) . IB3-1 cells are a CF human bronchial epithelial cell line derived from a CF patient compound heterozygous for the AF508 mutation (~F508/W1282X) (Zeitlin et al., 1991; Egan et al., 1992) . IB3-1 cells were grown as described previously in a modified LHC-8 medium (Zeitlin et al., 1991; Egan et al., 1992) .
Stable Transfection
DNA transfection of IB3-1 cells using lipofectin reagent (GIBCO BRL, Grand Island, NY) has been described previously in detail (Egan et al., 1992) . Both clones 315A and $9 were established with this method using adeno-associated viral (AAV) vectors containing the full-length, wild-type CFTR cDNA (Egan et al., 1992; Flotte et al. 1993) .
Transient Transfection
Transient transfection of IB3-1 cells was achieved by using a Rous sarcoma virus (RSV) promoter-driven mammalian expression vector (pAvS6-wtCFTR) containing the wild-type CFTR cDNA or with a second generation RSV vector (pRSV-wtCFTR) and lipofectin reagent. Both CFTR-containing RSV vectors complemented successfully cAMPstimulated ~CI-efflux from IB3-1 CF cells (Fulmer et al., 1995) . Lipofection was performed according to the guidelines of the manufacturer, with the only modification being continued incubation of DNA-lipofectin complexes in medium containing serum overnight following the 8 hr incubation in serum-free conditions (Fulmer et al., 1995) .
Whole Cell Patch-Clamp Recording
Whole-cell patch-clamp recording was performed as described previously in detail on airway epithelial cells grown on glass coverslips (3 mm diameter; Bellco Glass, Vineland, NJ) coated with Vitrogen (human collagen, Collagen Corporation, Palo Alto, CA) under the conditions described above. In these recordings, the bath solution contained 145 mM Tris-HCI, 1 mM CaCI2, 1 mM MgCI2, 5 mM glucose, 60 mM sucrose, and 5 mM N-2-hydroxyathylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.45), and 0.2 ~m filtered. The pipette solution contained Tris-HCI (145 raM), HEPES (5 raM), Ca 2+ and Mg2÷ (100 nM each chelated with 2 mM EGTA), and Mg2+-ATP (pH 7.45), and 0.2 ~m filtered. These solutions were designed to study only current flowing through CI-channels, since CI-was the only significant permeant ion in solution (Schwiebert et al., 1994a) , to clamp intracellular Ca 2+ at approximately 100 nM, and to prevent swelling-activated CIcurrents with added sucrose in the bath solution (Worrell et al., 1989) .
Single-Channel Patch-Clamp Recording
Single-channel patch-clamp recordings were carried out in the excised inside-out patch-clamp configuration by using conventional procedures (Hamill et al., 1981; Egan et al., 1992) . Catalytic subunit of PKA (50 nM; Promega, Madison, WI) and Mg-ATP (1 mM; Sigma, St. Louis, MO) were added to the cytoplasmic face of excised patches to activate the channels. All single-channel patch-clamp studies were performed at 25°C, since previous studies have shown that spontaneous activation of ORCCs does not occur at this temperature with patch excision (Egan et al., 1992) . Cell-attached recording was also carried out with the pipette solution (see below) being present in pipette and bath but with 500 nM Mg2+-ATP in both pipette and bath solutions as an agonist. Recording was begun immediately after formation of the cell-attached patch. Integrity of the cell-attached patch was confirmed by visualizing the membrane patch ripping away from the cell as the patch was excised to form the inside-out configuration. Currents were amplified with an Axopatch 200A patch-clamp amplifier and recorded on videotape for later analysis. Data were low-pass filtered at 500 Hz and digitized at 1 kHz. Data were analyzed with pCLAMP 5.5.1 software. The bath solution contained 141 mM NaCI, 2 mM MgCI2, 1 mM EGTA, 5 mM HEPES, and 0.5 mM CaCI2 (free Ca 2+ is 110 nM measured by Fura-2) (pH 7.3), 0.2 ~m filtered. The pipette solution contained 141 mM NaCI, 2 mM CaCI2, 2 mM MgCI2, 5 mM HEPES, 5 mM glucose (pH 7.3), 0.2 p.m filtered.
For single-channel recordings of ATP-versus CI-currents, standard 141 mM NaCI bath solution was exchanged for a nominally Cl=-free Na2-ATP solution that contained 40 mM Na gluconate, 50 mM Na2-ATP, 0.25 mM Ca gluconate, 1 mM EGTA, 5 mM HEPES (pH 7.4). For complete elimination of CI-in pipette and bath solutions, the pipette solution was 140 mM Na gluconate, 0.5 mM Ca gluconate, 5 mM HEPES (pH 7.4). For elimination of Na ÷ from the solutions, 140 mM Tris-CI and 140 mM Tris-ATP were substituted for NaCI (all other constituents were similar).
Short-Circuit Current Recording
For short-circuit current experiments, rat tracheal epithelial cells were isolated by a three-step process. First, tracheas were excised surgically from anesthetized rats. Second, excised tracheas were fileted open, and the tissue was subjected to 0.1% protease (Sigma) digestion overnight at 4°C with gentle agitation. Third, epithelial cells were scraped off the fileted tracheas, recovered by centrifugation, washed several times, resuspended as a homogeneous suspension in a modified LHC-8 medium (Biofluids, Rockville, MD) containing 5% fetal bovine serum (GIBCO BRL), and seeded onto collagen gels or onto permeable filters (12 mm SnapWell Transwell filter-bottom cups, Costar) for primary culture. The cultures were fed daily on the basolateral side of the monolayer, while the apical side was left exposed to the humidified, 50/0 CO2 environment. Confluence was achieved 3-4 days after initial seeding, and the monolayers were studied after 6-10 days in culture. Transepithelial resistances (RTE) were measured with an EVOM meter (World Precision Instruments, Sarasota, FL) and by calculating the resistance on the basis of measurement of basal transepithelial current and voltage after mounting the monolayer into the Ussing chamber. RTE ranged routinely from approximately 1000 to 2000 Q/cm 2 for cells grown on either collagen gels or filter supports. RTE was also routinely judged to be optimal once medium no longer leaked across the monolayer to the apical side devoid of medium.
The bath solution during Ussing chamber recordings was warmed to 37°C and contained 140 mM NaCI, 5 mM K2HPO4, 0.5 mM KH2PO4, 1.2 mM CaCI2, 1.2 mM MgCI2, 5 mM HEPES, 5 mM glucose (pH 7.4). Ag-AgCI wires embedded in 3 M KCI-agar bridges were used as voltage and current electrodes on each side of the monolayer contained in a perfused Ussing chamber system (World Precision Instruments), and voltage was clamped by a DVC-1000 voltage-clamp amplifier (World Precision Instruments) with a digital current and voltage readout and was attached to a strip-chart recorder for generation of real-time current traces.
[y-32P]ATP Release Assay
[y-~P]ATP (3000 Ci/mmol specific activity; 0.5 mCi per 6-well plate; New England Nuclear-DuPont) was loaded into cells via a three-step protocol: first, 15 min permeabilization with Streptolysin O (1 U/ml; Sigma) in a buffer containing 140 mM NaCI, 100 mM piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES), 5 mM glucose, 2.7 mM KCI, 2.7 mM EGTA, 1 mM Na2-ATP (pH 7.4), with 0.1o/0 bovine serum albumin and 0.25 mCi of [y-32P]ATP; second, three 5 min washes with a Ringer's solution containing 140 mM NaCI, 1.5 mM CaCI2, 1 mM MgCI2, 5 mM HEPES, 5 mM glucose, 5 mM K2HPOJKH2PO4, (pH 7.4); and third, 2 hr incubation in the same Ringer's solution with another dose of 0.25 mCi of [y-~P]ATP. Before starting release assay time course, cells were washed five times with ice-cold Ringer's. Ringer's warmed to 37°C with or without CPT-cAMP and always with 1 U/ml hexokinase to trap [y-32P]ATP as glucose-6-~2P was added at time 0 rain and extracted at four time points between 0 and 10 min. The four samples were pooled and normalized as counts referable to generation of glucose-6-~P. To determine the percent of counts referable to generated glucose-6J2p, free phosphate or labeled phospholipids were trapped from samples with an equal volume (1 ml) of 50/0 (wt/vol) ammonium molybdate in 0.85 N sulfuric acid and extracted with an equal volume of butanol, and the aqueous phase was counted and compared with unextracted samples (Ambudkar and Maloney, 1984) . Reproducibly, 75%-80% of the counts after extraction remained as glucose-6-phosphate. Alternatively, samples from a separate series of experiments were repeated in cells loaded with [7-~P]ATP but with [3H]glucose in the bath. After the experiment, extracted samples were compared with unextracted samples as above. Each sample was loaded on an anion-exchange column containing anion-exchange resin AG 1-X2 (Bio-Rad). The column was washed five times with water to remove free labeled glucose. Alkaline phosphatase (1 U/ml, Sigma) was added to the column to cleave off labeled glucose bound to the column as [3H]glucose-6-32P. Bound labeled 32p was eluted from the column in increasing NaCI concentrations (0 to 500 raM). After correcting for specific activity of [3H]glucose and [7-32P]ATP, extracted samples had an approximate 1:1 ratio of [3H]glucose to 3=p, indicative of pure glucose-6-phosphate in the extracted samples. In unextracted samples, the ratio of [3H]glucose to ~P was 0.75:1, which agreed with the extraction values shown above and suggests that 75% of ~P was complexed with glucose as glucose-6-phosphate and 25% was free 32p or labeled phospholipid in this experimental assay.
Statistics
All physiological assays were performed in a paired manner unless otherwise noted; thus, a paired Student's t test was used to assess statistical significance. A P value of <0.05 was considered significant. Data are expressed as mean _+ SEM. In some figures, basal conductance was subtracted from the stimulated conductance to graph more simply cAMP-activated conductance or ATP-stimulated conductance.
Materials
All compounds were obtained from Sigma unless otherwise noted. CPT-cAMP was purchased from Boehringer Mannheim (Indianapolis, IN), DIDS was Obtained from Sigma, and DPC was obtained from Fluka Biochemica (Switzerland). TS-TM-calix[4]arane (TS-TM-Calix4) was a gift of Dr. A. Singh and Dr. R. Bridges of the University of Alabama a~t Birmingham. CPT-cAMP bath solutions and ATP and other nucleotide stocks were made fresh dairy. DIDS, DPC, glybenclamide (glyburide) and TS-TM-Calix4 were made up as concentrated stocks and stored at 4°C. The sources of all other reagents are identified at the point they are discussed in the Experimental Procedures.
